
Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results in its ongoing Phase III …

France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …

